MANATEC

Manatec specializes in impedance cardiography devices, which measure cardiac output and hemodynamic parameters in real-time. These devices use bioimpedance technology to provide non-invasive monitoring of fluid status, cardiac function, and patient responses to treatments. Their products are primarily designed for critical care and perioperative settings, such as intensive care units and operating rooms.

Manatec is based in the United States, which means its devices must comply with U.S. regulatory standards, including those set by the FDA. Since its products fall under Class II classification, they undergo specific regulatory pathways to ensure safety and performance before authorization. The company’s U.S. location also influences its participation in domestic registries like the FDA’s Unique Device Identifier (UDI) database.

Manatec’s devices are listed in the FDA’s Unique Device Identifier (UDI) database. This registry is critical because it provides standardized identification for medical devices, improving traceability, safety monitoring, and compliance tracking. Listing in the UDI database ensures transparency for healthcare providers, regulators, and patients regarding the authorized devices in use.

Manatec’s devices are classified as Class II under FDA regulations, which means they pose moderate risks and require special controls to ensure their safety and effectiveness. This classification involves additional scrutiny during the authorization process, including performance testing and labeling requirements, to mitigate potential risks while allowing broader clinical use compared to higher-risk Class III devices.